Key result
Prasugrel reduced ischemic events compared to clopidogrel in ACS patients meeting EU label criteria, without a significant increase in major bleeding.
Why the study?
The EU label for prasugrel recommends treatment for up to 12 months with specific dosing and patient exclusions based on TRITON-TIMI 38 trial data, but outcomes for the 10 mg indicated cohort were not previously analyzed separately.
Does prasugrel 10 mg reduce ischemic events compared to clopidogrel in ACS patients meeting EU label criteria?
RCT (n=10,804)
Does prasugrel 10 mg reduce ischemic events compared to clopidogrel in ACS patients meeting EU label criteria?
In ACS patients meeting EU label criteria (age <75, weight ≥60 kg, no prior stroke/TIA), prasugrel 10 mg significantly reduces ischemic events compared to clopidogrel without a significant increase in major bleeding.
Answers are grounded in this paper and cite their sources.
Real-world prasugrel prescribing may deviate from EU label criteria; leaves open questions on safety and optimal duration in broader populations.
BACKGROUND: In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14.5 (maximum of 15) months. Based on this trial, the EU label for prasugrel recommends treatment for up to 12 months and excludes patients with prior stroke/transient ischemic attack (TIA). Furthermore, the EU label recommends the 10 mg maintenance dose (MD) for patients with body weight ≥60 kg and age <75 years. A lower MD of 5 mg is recommended for those with body weight <60 kg; although generally not recommended, 5 mg can be prescribed to patients ≥75 years after individual risk-benefit evaluation. This paper presents the one-year outcome data for this '10 mg indicated cohort'. METHODS AND RESULTS: From the overall cohort of 13,608 patients in TRITON-TIMI 38, 10,804 fulfilled inclusion criteria for the 10 mg indicated cohort, of whom 22% had a history of diabetes, 73% an index diagnosis of unstable angina/non-ST-segment-elevation myocardial infarction (UA/NSTEMI), and 27% an index diagnosis of ST-segment-elevation myocardial infarction (STEMI). In this cohort at 12 months, those given prasugrel experienced significantly fewer ischemic events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, 7.8% vs 10.5%, hazard ratio (HR) = 0.73, p < 0.001, than those given clopidogrel, with a non-significant increase in non-coronary artery bypass graft (CABG) TIMI major bleeding, 1.7% vs 1.5%, HR = 1.15, p = 0.40; similarly, in the overall cohort these frequencies were 9.4% vs 11.4%, HR = 0.81, p < 0.001, for cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, and 2.2% vs 1.8%, HR = 1.24, p = 0.10, for non-CABG TIMI major bleeding. There was a significant reduction in stent thrombosis in the prasugrel group, with similar mortality rates and no excess of strokes. CONCLUSIONS: Treatment with prasugrel according to EU label recommendations results in a significant 27% and 57% relative risk reduction (absolute risk reductions of 2.7% and 1.2%) in ischemic events and stent thromboses respectively compared with clopidogrel, with a 15% relative risk increase (absolute risk increase of 0.2%) for major bleeds (p = 0.40), and no excess of strokes. LIMITATIONS: Although restricted to 365 days of follow-up, this analysis encapsulates 1366 of 1424 (95.9%) of all primary endpoint events and 244 of 257 (94.9%) of all first non-CABG TIMI major bleeds reported in the pivotal manuscript. Furthermore, the 10 mg indicated cohort was not a pre-specified subgroup in the study protocol, but due to European labeling restrictions, results for all outcomes in this cohort are presented through 12 months.
No takes yet. Share an insight, caveat, or question.
Wilcox et al. (2014) conducted an RCT in Acute coronary syndromes (n=10,804). Prasugrel vs. Clopidogrel was evaluated on Ischemic events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) (HR 0.73, p=< 0.001). Prasugrel reduced ischemic events compared to clopidogrel in ACS patients meeting EU label criteria, without a significant increase in major bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: